206 related articles for article (PubMed ID: 23383318)
21. Pharmacological Characterization of the Spectrum of Antiviral Activity and Genetic Barrier to Drug Resistance of M2-S31N Channel Blockers.
Ma C; Zhang J; Wang J
Mol Pharmacol; 2016 Sep; 90(3):188-98. PubMed ID: 27385729
[TBL] [Abstract][Full Text] [Related]
22. Mechanisms of Action of Novel Influenza A/M2 Viroporin Inhibitors Derived from Hexamethylene Amiloride.
Jalily PH; Eldstrom J; Miller SC; Kwan DC; Tai SS; Chou D; Niikura M; Tietjen I; Fedida D
Mol Pharmacol; 2016 Aug; 90(2):80-95. PubMed ID: 27193582
[TBL] [Abstract][Full Text] [Related]
23. Site-directed M2 proton channel inhibitors enable synergistic combination therapy for rimantadine-resistant pandemic influenza.
Scott C; Kankanala J; Foster TL; Goldhill DH; Bao P; Simmons K; Pingen M; Bentham M; Atkins E; Loundras E; Elderfield R; Claridge JK; Thompson J; Stilwell PR; Tathineni R; McKimmie CS; Targett-Adams P; Schnell JR; Cook GP; Evans S; Barclay WS; Foster R; Griffin S
PLoS Pathog; 2020 Aug; 16(8):e1008716. PubMed ID: 32780760
[TBL] [Abstract][Full Text] [Related]
24. Rational design of a deuterium-containing M2-S31N channel blocker UAWJ280 with
Cáceres CJ; Hu Y; Cárdenas-García S; Wu X; Tan H; Carnaccini S; Gay LC; Geiger G; Ma C; Zhang QY; Rajao D; Perez DR; Wang J
Emerg Microbes Infect; 2021 Dec; 10(1):1832-1848. PubMed ID: 34427541
[TBL] [Abstract][Full Text] [Related]
25. Virtual screening and molecular growth guide the design of inhibitors for the influenza virus drug-resistant mutant M2-V27A/S31N.
Deng C; Wang X; Wang T; Liu W; Yuan X; Huang Y; Cao S
J Biomol Struct Dyn; 2024 Jul; 42(10):5253-5267. PubMed ID: 37424098
[TBL] [Abstract][Full Text] [Related]
26. Design and synthesis of pinanamine derivatives as anti-influenza A M2 ion channel inhibitors.
Zhao X; Jie Y; Rosenberg MR; Wan J; Zeng S; Cui W; Xiao Y; Li Z; Tu Z; Casarotto MG; Hu W
Antiviral Res; 2012 Nov; 96(2):91-9. PubMed ID: 22982118
[TBL] [Abstract][Full Text] [Related]
27. Crystal structure of the drug-resistant S31N influenza M2 proton channel.
Thomaston JL; DeGrado WF
Protein Sci; 2016 Aug; 25(8):1551-4. PubMed ID: 27082171
[TBL] [Abstract][Full Text] [Related]
28. An assay suitable for high throughput screening of anti-influenza drugs.
Mao L; Wang J; DeGrado WF; Inouye M
PLoS One; 2013; 8(1):e54070. PubMed ID: 23326573
[TBL] [Abstract][Full Text] [Related]
29. The L46P mutant confers a novel allosteric mechanism of resistance toward the influenza A virus M2 S31N proton channel blockers.
Musharrafieh R; Lagarias PI; Ma C; Tan GS; Kolocouris A; Wang J
Mol Pharmacol; 2019 Aug; 96(2):148-157. PubMed ID: 31175183
[TBL] [Abstract][Full Text] [Related]
30. [Design of an Efficient Inhibitor for the Influenza A Virus M2 Ion Channel].
Vorobjev YN
Mol Biol (Mosk); 2020; 54(2):321-332. PubMed ID: 32392203
[TBL] [Abstract][Full Text] [Related]
31. Structural comparison of the wild-type and drug-resistant mutants of the influenza A M2 proton channel by molecular dynamics simulations.
Gu RX; Liu LA; Wang YH; Xu Q; Wei DQ
J Phys Chem B; 2013 May; 117(20):6042-51. PubMed ID: 23594107
[TBL] [Abstract][Full Text] [Related]
32. Flipping in the pore: discovery of dual inhibitors that bind in different orientations to the wild-type versus the amantadine-resistant S31N mutant of the influenza A virus M2 proton channel.
Wu Y; Canturk B; Jo H; Ma C; Gianti E; Klein ML; Pinto LH; Lamb RA; Fiorin G; Wang J; DeGrado WF
J Am Chem Soc; 2014 Dec; 136(52):17987-95. PubMed ID: 25470189
[TBL] [Abstract][Full Text] [Related]
33. X-ray Crystal Structures of the Influenza M2 Proton Channel Drug-Resistant V27A Mutant Bound to a Spiro-Adamantyl Amine Inhibitor Reveal the Mechanism of Adamantane Resistance.
Thomaston JL; Konstantinidi A; Liu L; Lambrinidis G; Tan J; Caffrey M; Wang J; Degrado WF; Kolocouris A
Biochemistry; 2020 Feb; 59(4):627-634. PubMed ID: 31894969
[TBL] [Abstract][Full Text] [Related]
34. Steered molecular dynamics approach for promising drugs for influenza A virus targeting M2 channel proteins.
Nguyen H; Le L
Eur Biophys J; 2015 Sep; 44(6):447-55. PubMed ID: 26033540
[TBL] [Abstract][Full Text] [Related]
35. Structural and energetic analysis of drug inhibition of the influenza A M2 proton channel.
Gu RX; Liu LA; Wei DQ
Trends Pharmacol Sci; 2013 Oct; 34(10):571-80. PubMed ID: 24011996
[TBL] [Abstract][Full Text] [Related]
36. Discovery of Highly Potent Inhibitors Targeting the Predominant Drug-Resistant S31N Mutant of the Influenza A Virus M2 Proton Channel.
Li F; Ma C; DeGrado WF; Wang J
J Med Chem; 2016 Feb; 59(3):1207-16. PubMed ID: 26771709
[TBL] [Abstract][Full Text] [Related]
37. Isocyanides as Influenza A Virus Subtype H5N1 Wild-Type M2 Channel Inhibitors.
Wu S; Huang J; Gazzarrini S; He S; Chen L; Li J; Xing L; Li C; Chen L; Neochoritis CG; Liao GP; Zhou H; Dömling A; Moroni A; Wang W
ChemMedChem; 2015 Nov; 10(11):1837-45. PubMed ID: 26506405
[TBL] [Abstract][Full Text] [Related]
38. Coexistence of two adamantane binding sites in the influenza A M2 ion channel.
Rosenberg MR; Casarotto MG
Proc Natl Acad Sci U S A; 2010 Aug; 107(31):13866-71. PubMed ID: 20643947
[TBL] [Abstract][Full Text] [Related]
39. Discovery of potential M2 channel inhibitors based on the amantadine scaffold via virtual screening and pharmacophore modeling.
Tran L; Choi SB; Al-Najjar BO; Yusuf M; Wahab HA; Le L
Molecules; 2011 Dec; 16(12):10227-55. PubMed ID: 22158591
[TBL] [Abstract][Full Text] [Related]
40. Tackling Influenza A virus by M2 ion channel blockers: Latest progress and limitations.
Kumar G; Sakharam KA
Eur J Med Chem; 2024 Mar; 267():116172. PubMed ID: 38330869
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
